DRGS Global Big Pharma ETN
- Health & Biotech Equities
DRGS - Profile
- Issuer: RBS
- Structure: ETN
- Expense Ratio: 0.60%
- ETF Home Page: DRGS
- Inception: Oct 24, 2011
- Tax Form: 1099
- DRGS Tracks This Index: NYSE Arca Equal Weighted Pharmaceutical Total Return Index
- 52 Week Lo: $37.30
- 52 Week Hi: $59.00
- AUM: $9.4 M
- Shares: 0.2 M
Alternative ETFs in the Health & Biotech Equities Category
|Type||Ticker||Expense Ratio||Assets||Avg. Daily Vol||YTD Return|
|Most Liquid (Volume)|
|Top YTD Performer|
The index is designed to track the performance of the equity securities of a cross-section of global companies involved in various phases of the development, production and marketing of pharmaceuticals.
DRGS - Realtime Rating
Realtime Rating Summary
DRGS is a passive ETN that seeks to replicate NYSE Arca Equal Weighted Pharmaceutical Total Return Index. The index is designed to track the performance of the equity securities of a cross-section of global companies involved in various phases of the development, production and marketing of pharmaceuticals.
The adjacent table gives investors an individual Realtime Rating for DRGS on several different metrics, including liquidity, expenses, performance, volatility, dividend, concentration of holdings in addition to an overall rating. The "A+ Metric Rated ETF" field, available to ETFdb Pro members, shows the ETF in the Health & Biotech Equities with the highest Metric Realtime Rating for each individual field. To view all of this data, sign up for a free 14-day trial for ETFdb Pro. To view information on how the ETFdb Realtime Ratings work, click here.
DRGS In-Depth Analysis
The following tables and charts contain in-depth metrics for DRGS and compare it to similar peer ETFs within its ETFdb Category.
DRGS - Expenses & Fees
This section compares the cost efficiency of DRGS to peers in the same ETFdb Category.
Expenses Ratio Analysis
Commission Free Trading in DRGS
DRGS is not currently available for commission free trading on any platforms.
Category Commission Free Trading
There are 3 other ETFs in the Health & Biotech Equities ETFdb Category that are also eligible for commission free trading:
DRGS - Performance
This section shows how DRGS has performed relative to its peer group ETFdb Category.
DRGS - Charts
The following charts can be customized to display historical performance in a number of different formats, including line charts, bar charts, and candlesticks. Time periods can be adjusted to increase or decrease the period shown, ranging from five minutes to several months.
The following chart also includes the option to compare the performance of DRGS relative to other ETFs and benchmarks or to include indicators such as Bollinger Bands, relative strength, and moving averages.
DRGS - Technicals
DRGS Volatility Analysis
This section shows how the volatility of DRGS compares to the peer group ETFdb Category.
- 20 Day MA: $56.69
- 60 Day MA: $54.74
- MACD 15 Period: 1.59
- MACD 100 Period: 5.77
- Williams % Range 10 Day: 5.23
- Williams % Range 20 Day: 3.28
- RSI 10 Day: 71
- RSI 20 Day: 66
- RSI 30 Day: 64
- Ultimate Oscillator: 73
DRGS Bollinger Bands
- Lower Bollinger (10 Day): $56.30
- Upper Bollinger (10 Day): $59.86
- Lower Bollinger (20 Day): $53.51
- Upper Bollinger (20 Day): $59.90
- Lower Bollinger (30 Day): $52.95
- Upper Bollinger (30 Day): $59.28
DRGS Support & Resistance
- Support Level 1: $58.72
- Support Level 2: $58.58
- Resistance Level 1: $58.92
- Resistance Level 2: $58.98
- Stochastic Oscillator %D (1 Day): 71.70
- Stochastic Oscillator %D (5 Day): 73.14
- Stochastic Oscillator %K (1 Day): 59.80
- Stochastic Oscillator %K (5 Day): 81.66
Latest DRGS News
Obama Victory Puts Healthcare ETFs In Focus
October ETF Roundup: Launches, Filings, and Closures
This Week In ETFs: October 30th Edition
2014 Morningstar, Inc. All Rights Reserved. The information contained herein: ( 1 ) is proprietary to Morningstar and/or its content providers; ( 2 ) may not be copied or distributed; and ( 3 ) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.